Cargando…

Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients

INTRODUCTION: The predictive value of the pre-radiosurgery Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR) and the modified Glasgow Prognostic Score (mGPS) was assessed for the first time in a homogenous group of NSCLC brain metastaes (BM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Anna, Untersteiner, Helena, Hirschmann, Dorian, Fitschek, Fabian, Dorfer, Christian, Rössler, Karl, Zöchbauer-Müller, Sabine, Gatterbauer, Brigitte, Hochmair, Maximilian J., Frischer, Josa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875838/
https://www.ncbi.nlm.nih.gov/pubmed/33179214
http://dx.doi.org/10.1007/s11060-020-03660-z
_version_ 1783649846796746752
author Cho, Anna
Untersteiner, Helena
Hirschmann, Dorian
Fitschek, Fabian
Dorfer, Christian
Rössler, Karl
Zöchbauer-Müller, Sabine
Gatterbauer, Brigitte
Hochmair, Maximilian J.
Frischer, Josa M.
author_facet Cho, Anna
Untersteiner, Helena
Hirschmann, Dorian
Fitschek, Fabian
Dorfer, Christian
Rössler, Karl
Zöchbauer-Müller, Sabine
Gatterbauer, Brigitte
Hochmair, Maximilian J.
Frischer, Josa M.
author_sort Cho, Anna
collection PubMed
description INTRODUCTION: The predictive value of the pre-radiosurgery Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR) and the modified Glasgow Prognostic Score (mGPS) was assessed for the first time in a homogenous group of NSCLC brain metastaes (BM) patients. METHODS: We retrospectively evaluated 185 NSCLC-BM patients, who were treated with Gamma Knife Radiosurgery (GKRS). Patients with immunotherapy or targeted therapy were excluded. Routine laboratory parameters were reviewed within 14 days before GKRS1. RESULTS: Median survival after GKRS1 was significantly longer in patients with NLR < 5 (p < 0.001), PLR < 180 (p = 0.003) and LMR ≥ 4 (p = 0.023). The Cox regression model for the continuous metric values revealed that each increase in the NLR of 1 equaled an increase of 4.3% in risk of death (HR: 1.043; 95%CI = 1.020–1.067, p < 0.001); each increase in the PLR of 10 caused an increase of 1.3% in risk of death (HR: 1.013; 95%CI = 1.004–1.021; p = 0.003) and each increase in the LMR of 1 equaled a decrease of 20.5% in risk of death (HR: 0.795; 95%CI = 0.697–0.907; p = 0.001). Moreover, the mGPS group was a highly significant predictor for survival after GKRS1 (p < 0.001) with a HR of 2.501 (95%CI = 1.582–3.954; p < 0.001). NLR, PLR, LMR values and mGPS groups were validated as independent prognostic factors for risk of death after adjusting for sex, KPS, age and presence of extracranial metastases. CONCLUSION: NLR, PLR, LMR and mGPS represent effective and simple tools to predict survival in NSCLC patients prior to radiosurgery for brain metastases.
format Online
Article
Text
id pubmed-7875838
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-78758382021-02-22 Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients Cho, Anna Untersteiner, Helena Hirschmann, Dorian Fitschek, Fabian Dorfer, Christian Rössler, Karl Zöchbauer-Müller, Sabine Gatterbauer, Brigitte Hochmair, Maximilian J. Frischer, Josa M. J Neurooncol Clinical Study INTRODUCTION: The predictive value of the pre-radiosurgery Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR) and the modified Glasgow Prognostic Score (mGPS) was assessed for the first time in a homogenous group of NSCLC brain metastaes (BM) patients. METHODS: We retrospectively evaluated 185 NSCLC-BM patients, who were treated with Gamma Knife Radiosurgery (GKRS). Patients with immunotherapy or targeted therapy were excluded. Routine laboratory parameters were reviewed within 14 days before GKRS1. RESULTS: Median survival after GKRS1 was significantly longer in patients with NLR < 5 (p < 0.001), PLR < 180 (p = 0.003) and LMR ≥ 4 (p = 0.023). The Cox regression model for the continuous metric values revealed that each increase in the NLR of 1 equaled an increase of 4.3% in risk of death (HR: 1.043; 95%CI = 1.020–1.067, p < 0.001); each increase in the PLR of 10 caused an increase of 1.3% in risk of death (HR: 1.013; 95%CI = 1.004–1.021; p = 0.003) and each increase in the LMR of 1 equaled a decrease of 20.5% in risk of death (HR: 0.795; 95%CI = 0.697–0.907; p = 0.001). Moreover, the mGPS group was a highly significant predictor for survival after GKRS1 (p < 0.001) with a HR of 2.501 (95%CI = 1.582–3.954; p < 0.001). NLR, PLR, LMR values and mGPS groups were validated as independent prognostic factors for risk of death after adjusting for sex, KPS, age and presence of extracranial metastases. CONCLUSION: NLR, PLR, LMR and mGPS represent effective and simple tools to predict survival in NSCLC patients prior to radiosurgery for brain metastases. Springer US 2020-11-11 2021 /pmc/articles/PMC7875838/ /pubmed/33179214 http://dx.doi.org/10.1007/s11060-020-03660-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Cho, Anna
Untersteiner, Helena
Hirschmann, Dorian
Fitschek, Fabian
Dorfer, Christian
Rössler, Karl
Zöchbauer-Müller, Sabine
Gatterbauer, Brigitte
Hochmair, Maximilian J.
Frischer, Josa M.
Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title_full Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title_fullStr Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title_full_unstemmed Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title_short Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
title_sort pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875838/
https://www.ncbi.nlm.nih.gov/pubmed/33179214
http://dx.doi.org/10.1007/s11060-020-03660-z
work_keys_str_mv AT choanna preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT untersteinerhelena preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT hirschmanndorian preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT fitschekfabian preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT dorferchristian preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT rosslerkarl preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT zochbauermullersabine preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT gatterbauerbrigitte preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT hochmairmaximilianj preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients
AT frischerjosam preradiosurgeryleucocyteratiosandmodifiedglasgowprognosticscorepredictsurvivalinnonsmallcelllungcancerbrainmetastasespatients